The clinical significance of circulating B cells secreting anti-glycoprotein IIb/IIIa antibody and platelet glycoprotein IIb/IIIa in patients with primary immune thrombocytopenia

References

• Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008.
   PubMed Web of Science ®Google Scholar
• Cooper N, Bussel J. The pathogenesis of immune thrombocytopenic purpura. Br J Haematol. 2006;133(4):364–74.
   PubMed Web of Science ®Google Scholar
• Neunert C, Lim W, Crowther M, Cohen A, Solberg L, Crowther MA, et al. The American Society 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190–207.
   PubMed Web of Science ®Google Scholar
• Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clin Proc. 2004;79(4):504–22.
   PubMed Web of Science ®Google Scholar
• Ballem PJ, Segal GM, Stratton JR, Gernsheimer T, Adamson JW, Slichter SJ. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest. 1987;80(1):33–40.
   PubMed Web of Science ®Google Scholar
• McMillan R. Autoantobodies and autoantigens in chronic immune thrombocytopenia purpura. Semin Hematol. 2000;37(3):239–48.
   PubMed Web of Science ®Google Scholar
• Nugent D, McMillan R, Nichol JL, Slichter SJ. Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and/or decreased platelet production. Br J Haematol. 2009;146(6):585–96.
   PubMed Web of Science ®Google Scholar
• Chang M, Nakagawa PA, Williams SA, Schwartz MR, Imfeld KL, Buzby JS, et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood. 2003;102(3):887–95.
   PubMed Web of Science ®Google Scholar
• McMillan R, Wang L, Tomer A, Nichol J, Pistillo J. Suppression of in vitro megakaryocyte production by antiplatelet autoantibodies from adult patients with chronic ITP. Blood. 2004;103(4):1364–9.
   PubMed Web of Science ®Google Scholar
• Bao W, Bussel JB, Heck S, He W, Karpoff M, Boulad N, et al. Improved regulatory T cell activity in patients with chronic immune thrombocytopenia treated with thrombopoietic agents. Blood. 2010;116(22):4639–45.
   PubMed Web of Science ®Google Scholar
• Zhang F, Chu X, Wang L, Zhu Y, Li L, Ma D, et al. Cell-mediated lysis of autologous platelets in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 2006;76(5):427–31.
   PubMed Web of Science ®Google Scholar
• Olsson B, Andersson PO, Jernås M, Jacobbson S, Carlsson B, Carlsson LM, et al. T-cellmediated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nat Med. 2003;9(9):1123–4.
   PubMed Web of Science ®Google Scholar
• Hou M, Stockelberg D, Kutti J, Waldenvik H. Antibodies against GPIb/IX, GPIIb/IIIa, and other platelet antigens in chronic idiopathic thrombocytopenic purpura. Eur J Haematol. 1995;55(5):307–14.
   PubMed Web of Science ®Google Scholar
• Mehta YS, Pathare AV, Badakere SS, Ghosh K, Mohanty D. Influence of auto-antibody specificities on the clinical course in patients with chronicand acute ITP. Platelets. 2000;11(2):94–8.
   PubMed Web of Science ®Google Scholar
• Fabris F, Scandellari R, Ruzzon E, Randi ML, Luzzato G, Girolami A. Plateletassociated autoantibodies as detected by a solidphase modified antigen capture ELISA test (MACE) are a useful prognostic factor in idiopathic thrombocytopenic purpura. Blood. 2004;103(12):4562–4.
   PubMed Web of Science ®Google Scholar
• van Leeuwen EF, van der Ven JT, Engelfriet CP, von dem Borne AE. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood. 1982;59(1):23–6.
   PubMed Web of Science ®Google Scholar
• He R, Reid DM, Jones CE, Shulman NR. Spectrum of Ig classes, specificities, and titers of serum antiglycoproteins in chronic idiopathic thrombocytopenic purpura. Blood. 1994;83(4):1024–32.
   PubMed Web of Science ®Google Scholar
• Woods VL, Oh EH, Mason D, McMillan R. Autoantibodies against the platelet glycoprotein IIb/IIIa complex in patients with chronic ITP. Blood. 1984;63(2):368–75.
   PubMed Web of Science ®Google Scholar
• Fujisawa K, Tani P, McMillan R. Plateletassociated antibody to glycoprotein IIb/IIIa from chronic immune thrombocytopenic purpura patients often binds to divalent cation-dependent antigens. Blood. 1993;81(5):1284–9.
   PubMed Web of Science ®Google Scholar
• Chan H, Moore JC, Finch CN, Warkentin TE, Kelton JG. The IgG subclasses of platelet associated autoantibodies directed against platelet glycoproteins IIb/IIIa in patients with idiopathic thrombocytopenic purpura. Br J Haematol. 2003;122(5):818–24.
   PubMed Web of Science ®Google Scholar
• Czerkinsky CC, Nilsson LA, Nygren H, Ouchterlony O, Tarkowski A. A solid-phase enzyme-linked immunospot (ELISPOT) assay for enumeration of specific antibody-secreting cells. J Immunol Methods. 1983;65(1–2):109–21.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Okazaki Y, Kaburaki J, Kawakami Y, Ikeda Y. Spleen is a primary site for activation of glycoprotein IIb-IIIa-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol. 2002;168(7):3657–82.
   Web of Science ®Google Scholar
• Kuwana M, Okazaki Y, Kaburaki J, Ikeda Y. Detection of circulating B cells secreting platelet-specific autoantibody is useful in the diagnosis of autoimmune thrombocytopenia. Am J Med. 2003;114(4):322–5.
   PubMed Web of Science ®Google Scholar
• Satoh T, Pandey JP, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y, et al. Single nucleotide polymorphisms of the inflammatory cytokine genes in adults with chronic immune thrombocytopenic purpura. Br J Haematol. 2004;124(6):796–801.
   PubMed Web of Science ®Google Scholar
• Cohen YC, Djulbegovic B, Shamai-Lubovitz O, Mozes B. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Int Med. 2000;160(11):1630–8.
   PubMed Web of Science ®Google Scholar
• Provan D, Stasi R, Newland AC, Blanchette VS, Bolton-Maggs P, Bussel JB, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168–86.
   PubMed Web of Science ®Google Scholar
• Hou M, Peng J, Shi Y, Zhang C, Qin P, Zhao C, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353–7.
   PubMed Web of Science ®Google Scholar
• McMillan R. The pathogenesis of chronic immune thrombocytopenic purpura. Semin Hematol. 2007;44 (4 Suppl 5):S3–S11.
   PubMed Web of Science ®Google Scholar
• Sakakura M, Wada H, Tawara I, Nobori T, Sugiyama T, Sagawa N, et al. Reduced CD4+CD25+ T cells in patients with idiopathic thrombocytopenic purpura. Thromb Res. 2007;120(2):187–93.
   PubMed Web of Science ®Google Scholar
• Yu J, Heck S, Patel V, Leva J, Yu Y, Bussel JB, et al. Defective circulating CD25+ regulatory T cells in patients with chronic immune thrombocytopenic purpura. Blood. 2008;112(4):1325–8.
   PubMed Web of Science ®Google Scholar
• Stasi R, Cooper N, Del Poeta G, Stipa E, Laura Evangelista M, Abruzzese E, et al. Analysis of regulatory T-cell changes in patients with idiopathic thrombocytopenic purpura receiving B cell-depleting therapy with rituximab. Blood. 2008;112(4):1147–50.
   PubMed Web of Science ®Google Scholar
• Mueller-Eckhardt C, Kayser W, Mersch-Baumert K, Mueller-Eckhardt G, Breidenbach M, Kugel HG, et al. The clinical significance of platelet-associated IgG: a study on 298 patients with various disorders. Br J Haematol. 1980;46(1):123–31.
   PubMed Web of Science ®Google Scholar
• Kelton JG, Powers PJ, Carter CJ. A prospective study of the usefulness of the measurement of platelet-associated IgG for the diagnosis idiopathic thrombocytopenic purpura. Blood. 1982;60(4):1050–3.
   PubMed Web of Science ®Google Scholar
• Brighton TA, Evans S, Castaldi PA, Chesterman CN, Chong BH. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenia. Blood. 1996;88(1):194–201.
   PubMed Web of Science ®Google Scholar
• Warner MN, Moore JC, Warkentin TE, Santos AV, Kelton JG. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol. 1999;104(3):442–7.
   PubMed Web of Science ®Google Scholar
• Raife TJ, Olson JD, Lentz SR. Platelet antibody testing in idiopathic thrombocytopenic purpura. Blood. 1997;89(3):1112–4.
   PubMed Web of Science ®Google Scholar
• Cines DB, Bussel JB, Liebman HA, Luning Prak ET. The ITP syndrome: pathogenic and clinical diversity. Blood. 2009;113(26):6511–21.
   PubMed Web of Science ®Google Scholar
• Wang JY, Chou CH, Lee LN, Hsu HL, Jan IS, Hsueh PR, et al. Diagnosis of tuberculosis by an enzyme-linked immunospot assay for interferon-gamma. Emerg Infect Dis. 2007;13(4):553–8.
   PubMed Web of Science ®Google Scholar
• Sedgwick JD. ELISPOT assay: a personal retrospective. Methods Mol Biol. 2005;302:3–14.
   PubMedGoogle Scholar
• Kuwana M, Kurata Y, Fujimura K, Fujisawa K, Wada H, Nagasawa T, et al. Preliminary laboratory based diagnostic criteria for immune thrombocytopenic purpura: evaluation by muti-center prospective study. J Thromb Haemost. 2006;4(9):1936–43.
   PubMed Web of Science ®Google Scholar
• Phillips DR, Charo IF, Parise LV, Fitzgerald LA. The platelet membrane glycoprotein IIb/IIIa complex. Blood. 1988;71(4):831–43.
   PubMed Web of Science ®Google Scholar
• Kuwana M, Kaburaki J, Kitasato H, Kato M, Kawai S, Kawakami Y, et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood. 2001;98(1):130–9.
   PubMed Web of Science ®Google Scholar